製品番号: HY-N0182

Fisetin

(別名: フィセチン)

32 Cited Publications

カスタマーレビュー

Based on 32 publication(s) in Google Scholar

Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.90%
CAS 番号: 528-48-3
分子式: C₁₅H₁₀O₆
分子量:286.24

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Fisetin 構造式

CAS 番号: 528-48-3

容量

価格（税別）

在庫状況

数量

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

バルクお問い合わせ

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (32)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
Bioz

生物活性

製品説明

Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.

IC₅₀ & Target

Sirtuin, PPAR, TNF-alpha^[1]^[2]

Sirtuin アイソフォーム固有の製品をすべて表示 :

PPAR アイソフォーム固有の製品をすべて表示 :

TNF Receptor アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
BV-2	IC₅₀	73.02 μM Compound: 13	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	[PMID: 28911817]
BV-2	IC₅₀	13.5 μM Compound: Fisetin	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS addition and measured after 24 hrs by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS addition and measured after 24 hrs by Griess assay	[PMID: 28923363]
BV-2	IC₅₀	13.5 μM Compound: 92	Anti-inflammatory activity against mouse BV-2 cells assessed as LPS-induced inhibition of NO production Anti-inflammatory activity against mouse BV-2 cells assessed as LPS-induced inhibition of NO production	[PMID: 37683361]
CWR22R	IC₅₀	25.9 μM Compound: 22	Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer	[PMID: 22789812]
DU-145	IC₅₀	>50 μM Compound: 2	Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay	[PMID: 28760528]
DU-145	IC₅₀	>50 μM Compound: Fisetin	Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay	[PMID: 30165345]
H9	EC₅₀	122 μM Compound: 14	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8158164]
H9	IC₅₀	157 μM Compound: 14	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8158164]
HepG2	IC₅₀	>400 μM Compound: 34	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21726077]
HT-22	EC₅₀	2.8 μM Compound: fisetin	Neuroprotective effect against iodoacetic acid-induced ischemia in mouse HT22 cells treated simultaneously with iodoacetic acid for 2 hrs followed by incubation in fresh medium containing drug alone for 20 hrs measured after 4 hrs by MTT assay Neuroprotective effect against iodoacetic acid-induced ischemia in mouse HT22 cells treated simultaneously with iodoacetic acid for 2 hrs followed by incubation in fresh medium containing drug alone for 20 hrs measured after 4 hrs by MTT assay	[PMID: 19537799]
HT-22	EC₅₀	3 μM Compound: Fisetin	Neuroprotective activity in mouse HT22 cells assessed as reduction in IAA-induced ischemia after 24 hrs by MTT assay Neuroprotective activity in mouse HT22 cells assessed as reduction in IAA-induced ischemia after 24 hrs by MTT assay	[PMID: 22192055]
Huh-7	CC₅₀	>50 μM Compound: 39	Cytotoxicity against human Huh7.5.1 cells by MTT assay Cytotoxicity against human Huh7.5.1 cells by MTT assay	[PMID: 22445328]
KB	ED₅₀	>100 μg/mL Compound: NSC-407010	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 469554]
L6	IC₅₀	>30 μg/mL Compound: 20	Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by photometric method Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by photometric method	10.1039/C5MD00481K
L6	IC₅₀	38.5 μg/mL Compound: 20	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence analysis Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence analysis	10.1039/C5MD00481K
LNCaP	IC₅₀	34.1 μM Compound: 2	Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay	[PMID: 28760528]
LNCaP	IC₅₀	34.1 μM Compound: Fisetin	Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay	[PMID: 30165345]
MCF-10A	IC₅₀	2.44 μM Compound: Fisetin	Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 3 days by WST-1 assay Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 3 days by WST-1 assay	[PMID: 30165345]
Monocyte	IC₅₀	3.7 μM Compound: fisetin	Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs	[PMID: 8882428]
Monocyte	IC₅₀	3.7 x 10^-6 M Compound: fisetin	Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs	[PMID: 8882428]
PC-3	IC₅₀	>50 μM Compound: 2	Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay	[PMID: 28760528]
PC-3	IC₅₀	>50 μM Compound: Fisetin	Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay	[PMID: 30165345]
PWR-1E	IC₅₀	5.39 μM Compound: Fisetin	Cytotoxicity against human PWR-1E cells assessed as decrease in cell viability after 3 days by WST-1 assay Cytotoxicity against human PWR-1E cells assessed as decrease in cell viability after 3 days by WST-1 assay	[PMID: 30165345]
RD	EC₅₀	84.48 μM Compound: Fisetin	Antiviral activity against EV71 infected in human RD cells assessed as reduction in viral plaque formation after 1 hr by crystal violet staining method Antiviral activity against EV71 infected in human RD cells assessed as reduction in viral plaque formation after 1 hr by crystal violet staining method	[PMID: 27776325]
THP-1	IC₅₀	30 μM Compound: Fisetin	Cytotoxicity against human THP1 cells after 24 hrs by MTS assay Cytotoxicity against human THP1 cells after 24 hrs by MTS assay	[PMID: 19879672]
THP-1	IC₅₀	30 μM/L Compound: Fisetin	Cytotoxicity against human THP1 cells after 24 hrs by MTS assay Cytotoxicity against human THP1 cells after 24 hrs by MTS assay	[PMID: 19879672]
Vero	IC₅₀	55 μg/mL Compound: fisetin	Antiviral activity against dengue virus 2 infected in african green monkey Vero cells assessed as reduction in viral replication dosed after adsorption with 200 FFU of virus for 1 hour by foci forming unit reduction assay Antiviral activity against dengue virus 2 infected in african green monkey Vero cells assessed as reduction in viral replication dosed after adsorption with 200 FFU of virus for 1 hour by foci forming unit reduction assay	[PMID: 25564380]

体外実験

Fisetin inhibits lipid accumulation and suppresses the expression of PPARγ in 3T3-L1 cells. Fisetin suppresses early stages of preadipocyte differentiation, and induces expression of Sirt1. Fisetin facilitates Sirt1-mediated deacetylation of PPARγ and FoxO1, and enhances the association of Sirt1 with the PPARγ promoter, leading to suppression of PPARγ transcriptional activity, thereby repressing adipogenesis^[1]. Fisetin binds to tubulin and stabilizes microtubules with binding characteristics far superior than paclitaxel. Fisetin treatment of human prostate cancer cells results in robust up-regulation of microtubule associated proteins (MAP)-2 and -4. Fisetin significantly inhibits PCa cell proliferation, migration, and invasion. Nudc, a protein associated with microtubule motor dynein/dynactin complex that regulates microtubule dynamics, is inhibited with Fisetin treatment^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Fisetin treatment to UVB exposed mice results in decreased hyperplasia and reduces infiltration of inflammatory cells. Fisetin treatment also reduces inflammatory mediators such as COX-2, PGE2 as well as its receptors (EP1- EP4), and MPO activity. Furthermore, Fisetin reduces the level of inflammatory cytokines TNFα, IL-1β and IL-6 in UVB exposed skin. Fisetin treatment also reduces cell proliferation markers as well as DNA damage as evidenced by increased expression of p53 and p21 proteins^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 528-48-3
性状 Solid
分子量 286.24
分子式 C₁₅H₁₀O₆
Color Light yellow to yellow
SMILES

O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC=C13
別名

フィセチン
Structure Classification
- Flavonoids
- Flavonols
- Phenols
- Polyphenols
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (32)

All Cell Imaging/StainingRT-PCRWBIF

Sort by:

Journal Impact Factor

Cell Stem Cell

Senolytic-sensitive p16Ink4a+ fibroblasts in the tumor stroma rewire lung cancer metabolism and plasticity. [Abstract]

2025 Dec 4;32(12):1869-1885.e8. PMID: 41187746
Nat Aging

Spatiotemporal transcriptomic changes of human ovarian aging and the regulatory role of FOXP1. [Abstract]

2024 Apr;4(4):527-545. PMID: 38594460

Fisetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Fisetin (10 μM, 24 h), Quercetin (10 μM, 24 h) delayed FOXP1 gene silencing-induced cellular senescence in COV434 cells.

Fisetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Fisetin (10 μM, 24 h), Quercetin (10 μM, 24 h) inhibited the FOXP1 silencing-induced increase in CDKN1A expression in COV434 cells.

Fisetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Fisetin (10 μM, 24 h) and Quercetin (10 μM, 24 h) reversed the decrease in COV434 cell proliferation induced by FOXP1 knockdown.

Fisetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Quercetin (10 μM, 24 h) but not Fisetin (10 μM, 24 h) delayed FOXP1 gene silencing in COV434 cells.

Fisetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Quercetin (10 μM, 24 h) but not Fisetin (10 μM, 24 h) decreased γH2AX levels in COV434 cells.
Autophagy

Restricting intracellular Salmonella proliferation by coordinating p-TBK1 mediated mitophagy and xenophagy. [Abstract]

2025 Jul 27:1-23. PMID: 40660474
Cell Rep Med

Targeting senescent EGR1+ B cells enhances immunotherapy efficacy in esophageal squamous cell carcinoma. [Abstract]

2026 Jan 20;7(1):102532. PMID: 41483805
Acta Pharmacol Sin

Fisetin treatment alleviates kidney injury in mice with diabetes-exacerbated atherosclerosis through inhibiting CD36/fibrosis pathway. [Abstract]

2023 Oct;44(10):2065-2074. PMID: 37225845
Aging Cell

2026 Jan 20;25(2):e70352.
JCI Insight

Neutrophil extracellular traps potentiate effector T cells via endothelial senescence in uveitis. [Abstract]

2025 Jan 23;10(2):e180248. PMID: 39846254
Biochem Pharmacol

NUF2 activated by YY1 promotes prostate cancer malignancy via p38/MAPK signaling axis and serves as a therapeutic target. [Abstract]

2025 Apr 3:116919. PMID: 40187571
Mol Cancer Ther

Harnessing senolytics and PARP inhibition to expand the antitumor activity of CDK4/6 inhibitors in prostate cancer. [Abstract]

2025 Jul 2. PMID: 40601842
J Ethnopharmacol

Study on the anti-skin aging effect and mechanism of Sijunzi Tang based on network pharmacology and experimental validation. [Abstract]

2024 Jun 14:118421. PMID: 38880400
Cells

EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263. [Abstract]

2022 Jun 21;11(13):1992. PMID: 35805077
J Mol Liq

23 November 2021, 118164.
Int J Mol Sci

Synergistic Induction of Caspase-8-Mediated Leukaemic Cell Death by Fisetin and Pinocembrin. [Abstract]

2026 Jun 22;27(12):5622. PMID: 42353336
Int J Mol Sci

Fisetin Attenuates Zinc Overload-Induced Hepatotoxicity in Mice via Autophagy-Dependent Nrf2 Activation. [Abstract]

2025 May 22;26(11):4978. PMID: 40507790
Biol Direct

GAMT facilitates tumor progression via inhibiting p53 in clear cell renal cell carcinoma. [Abstract]

2025 Apr 2;20(1):43. PMID: 40176130
J Nutr Biochem

F6P/G6P-mediated ChREBP activation promotes the insulin resistance-driven hepatic lipid deposition in zebrafish. [Abstract]

2023 Dec:122:109452. PMID: 37748621
Biomolecules

Targeting Cellular Senescence to Enhance Human Endometrial Stromal Cell Decidualization and Inhibit Their Migration. [Abstract]

2025 Jun 16;15(6):873. PMID: 40563513
Eur J Pharmacol

Fisetin suppresses ferroptosis through Nrf2 and attenuates intervertebral disc degeneration in rats. [Abstract]

2024 Feb 5:964:176298. PMID: 38145645
Molecules

Fisetin Delays Postovulatory Oocyte Aging by Regulating Oxidative Stress and Mitochondrial Function through Sirt1 Pathway. [Abstract]

2023 Jul 20;28(14):5533. PMID: 37513404
Hepatob Pancreat Dis

Fisetin mitigates hepatic ischemia-reperfusion injury by regulating GSK3β/AMPK/NLRP3 inflammasome pathway. [Abstract]

2021 Aug;20(4):352-360. PMID: 34024736
Eur J Nutr

Fisetin alleviates Salmonella typhimurium-induced colitis through the TLR2/TLR4-NF-κB pathway, regulating microbiota, and repressing intracellular bacterial proliferation by focal adhesion kinase. [Abstract]

2025 Mar 19;64(3):128. PMID: 40106033
Biochim Biophys Acta Mol Basis Dis

MISP-mediated enhancement of pancreatic cancer growth through the Wnt/β-catenin signaling pathway is suppressed by Fisetin. [Abstract]

2024 Sep 13:167515. PMID: 39278512
Fish Shellfish Immunol

Emodin enhances host antiviral immunity against Micropterus salmoides rhabdovirus by activating RLR signaling in largemouth bass. [Abstract]

2025 Aug 6:166:110633. PMID: 40769268
Aging (Albany NY)

Fisetin inhibits the proliferation, migration and invasion of pancreatic cancer by targeting PI3K/AKT/mTOR signaling. [Abstract]

2021 Nov 25;13(22):24753-24767. PMID: 34821587
Food Sci Nutr

Flavonoids in Rosa roxburghii Tratt Fermentation Broth Ameliorate Obesity via DNMT3a/SIRT1-Mediated Epigenetic Modulation. [Abstract]

2025 Sep 3;13(9):e70892. PMID: 40909259
Microbiol Spectr

Therapeutic potential of flavonols in the treatment of JCPyV. [Abstract]

2025 Aug 21:e0152725. PMID: 40838703
Naunyn Schmiedebergs Arch Pharmacol

Therapeutic use of fisetin and pirfenidone combination in bleomycin-induced pulmonary fibrosis in adult male albino rats. [Abstract]

2025 Feb;398(2):1665-1679. PMID: 39162796
PeerJ

Fisetin may protect early porcine embryos from oxidative stress by down-regulating GRP78 levels. [Abstract]

2025 Mar 28:13:e19198. PMID: 40166042
Biochem Biophys Res Commun

Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. [Abstract]

2018 Sep 3;503(1):297-303. PMID: 29890135
bioRxiv

Senescent fibroblasts in the tumor stroma rewire lung cancer metabolism and plasticity. [Abstract]

2024 Jul 30:2024.07.29.605645. PMID: 39131266
Journal of Harran University Medical Faculty

2023 Sep 6.
Research Square Preprint

2023 Nov 20.

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (349.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4936 mL

17.4679 mL

34.9357 mL

5 mM

0.6987 mL

3.4936 mL

6.9871 mL

10 mM

0.3494 mL

1.7468 mL

3.4936 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 45% PEG300 5% Tween-80 50% Saline

Solubility: 10 mg/mL (34.94 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 0.5% CMC/saline water

Solubility: 25 mg/mL (87.34 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

Cell Assay^[1]

3T3-L1 cells are transfected with reporter vector, and expression plasmids using TransIT-LT1. After 24 h, media is replaced with viral supernatant. After 15-18 h of infection, media is replaced with DMI, 0.1 μM troglitazone and Fisetin (50 μM). Cells are lysed using cell culture lysis buffer two days after addition of differentiation stimulus. Luciferase activity is determined using an analytical luminescence luminometer^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

Mice: The mice are divided into six groups of eight animals each. The mice in the first group are topically treated with 0.2 mL acetone and used as vehicle control. The mice in the second and third groups receive topical treatment of Fisetin 250 nmol/0.2 mL acetone/mouse and 500 nmol/0.2 mL acetone/mouse respectively on their dorsal skin and serves as agent controls. The mice in the fourth, fifth and sixth groups are exposed to UVB. The mice in the fourth group receive a topical application of 0.2 mL acetone after 15 min of UVB exposure designated as vehicle control. The mice in the fifth and sixth groups are treated with topical application of Fisetin 250 nmol/0.2 mL acetone/mouse and 500 nmol/0.2 mL acetone/mouse respectively on to their dorsal skin after 15 min of UVB exposure^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (279 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Kim SC, et al. Fisetin induces Sirt1 expression while inhibiting early adipogenesis in 3T3-L1 cells. Biochem Biophys Res Commun. 2015 Nov 27;467(4):638-44. [Content Brief]

[2]. Mukhtar E, et al. Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells. Cancer Lett. 2015 Oct 28;367(2):173-83. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.4936 mL	17.4679 mL	34.9357 mL	87.3393 mL
	5 mM	0.6987 mL	3.4936 mL	6.9871 mL	17.4679 mL
	10 mM	0.3494 mL	1.7468 mL	3.4936 mL	8.7339 mL
	15 mM	0.2329 mL	1.1645 mL	2.3290 mL	5.8226 mL
	20 mM	0.1747 mL	0.8734 mL	1.7468 mL	4.3670 mL
	25 mM	0.1397 mL	0.6987 mL	1.3974 mL	3.4936 mL
	30 mM	0.1165 mL	0.5823 mL	1.1645 mL	2.9113 mL
	40 mM	0.0873 mL	0.4367 mL	0.8734 mL	2.1835 mL
	50 mM	0.0699 mL	0.3494 mL	0.6987 mL	1.7468 mL
	60 mM	0.0582 mL	0.2911 mL	0.5823 mL	1.4557 mL
	80 mM	0.0437 mL	0.2183 mL	0.4367 mL	1.0917 mL
	100 mM	0.0349 mL	0.1747 mL	0.3494 mL	0.8734 mL

Keywords

Fisetin

32 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Fisetin

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

Medicine Food Homology Compound Library

Phenols Library

Pyroptosis Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Neuroprotective Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Nuclear Receptor Compound Library

Anti-Aging Natural Product Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

Flavor Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Fisetin

Sirtuin アイソフォーム固有の製品をすべて表示

PPAR アイソフォーム固有の製品をすべて表示

TNF Receptor アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (32)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Fisetin 関連分類

製品番号: HY-N0182